{"id":"carvedilol-empagliflozin","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypotension"},{"rate":null,"effect":"Bradycardia"},{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Genital mycotic infections"},{"rate":null,"effect":"Urinary tract infections"}]},"_chembl":{"chemblId":"CHEMBL2107830","moleculeType":"Small molecule","molecularWeight":"450.92"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Carvedilol blocks beta-adrenergic receptors to reduce heart rate, blood pressure, and myocardial oxygen demand, providing cardioprotective effects. Empagliflozin inhibits sodium-glucose cotransporter 2 (SGLT2) in the kidney to increase urinary glucose excretion and reduce blood glucose, while also providing cardiovascular and renal protective benefits through hemodynamic and metabolic mechanisms.","oneSentence":"Carvedilol+Empagliflozin combines a non-selective beta-blocker with an SGLT2 inhibitor to reduce heart workload and improve cardiac efficiency while promoting glucose excretion.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:05:00.380Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Heart failure with reduced ejection fraction"},{"name":"Type 2 diabetes mellitus with cardiovascular disease"}]},"trialDetails":[{"nctId":"NCT06844669","phase":"PHASE2","title":"HER2HEART-US: Prevention of Cardiotoxicity in Breast Cancer Patients Receiving HER2-directed Therapy","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2025-04-16","conditions":"HER2-positive Breast Cancer, HER2+ Breast Cancer","enrollment":7},{"nctId":"NCT07335900","phase":"NA","title":"A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis","status":"RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-12-19","conditions":"Severe Aortic Valve Stenosis","enrollment":25},{"nctId":"NCT07322237","phase":"PHASE4","title":"DICE Study- Diastolic Improvement With Carvedilol & Empagliflozin in Patients With Cirrhosis","status":"RECRUITING","sponsor":"Post Graduate Institute of Medical Education and Research, Chandigarh","startDate":"2026-01-01","conditions":"Cirrhotic Cardiomyopathy, Empagliflozin, Cardiometabolic Risk Factors","enrollment":400},{"nctId":"NCT06697353","phase":"","title":"An Observational Study to Learn More About the Real-world Outcomes in Patients With Heart Failure Who Initiate Treatment With Vericiguat in Japan","status":"COMPLETED","sponsor":"Bayer","startDate":"2024-11-01","conditions":"Chronic Heart Failure, Chronic Heart Failure With Reduced Ejection Fraction","enrollment":4936},{"nctId":"NCT06930092","phase":"NA","title":"RestoratIon of Myocardial Function by PeRcutaneous cOronary interVEntion in Patients With Ischemic CardioMyoPathy","status":"RECRUITING","sponsor":"Seoul National University Hospital","startDate":"2025-07-01","conditions":"Ischemic Cardiomyopathy","enrollment":158},{"nctId":"NCT05637853","phase":"PHASE4","title":"Telemonitored Fast Track Medical Sequencing for Heart Failure With Reduced Ejection Fraction","status":"ACTIVE_NOT_RECRUITING","sponsor":"Göteborg University","startDate":"2022-10-22","conditions":"Heart Failure With Reduced Ejection Fraction","enrollment":60},{"nctId":"NCT04345796","phase":"PHASE3","title":"Pharmacological Reduction of Right Ventricular Enlargement","status":"COMPLETED","sponsor":"Asan Medical Center","startDate":"2021-02-15","conditions":"Tricuspid Regurgitation, Right Ventricular Dilatation","enrollment":56},{"nctId":"NCT05580510","phase":"PHASE2, PHASE3","title":"\" Evaluation of Safety and Efficacy of Empagliflozin and Sacubitril/Valsartan for CHF With Reduced Ejection Fraction in ACHD \"","status":"UNKNOWN","sponsor":"Instituto Nacional de Cardiologia Ignacio Chavez","startDate":"2023-02-06","conditions":"Congenital Heart Disease, Heart Failure, Heart Failure With Reduced Ejection Fraction","enrollment":160}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Dilatrend SR+Jardiance"],"phase":"phase_3","status":"active","brandName":"Carvedilol+Empagliflozin","genericName":"Carvedilol+Empagliflozin","companyName":"Asan Medical Center","companyId":"asan-medical-center","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Carvedilol+Empagliflozin combines a non-selective beta-blocker with an SGLT2 inhibitor to reduce heart workload and improve cardiac efficiency while promoting glucose excretion. Used for Heart failure with reduced ejection fraction, Type 2 diabetes mellitus with cardiovascular disease.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}